Literature DB >> 27114646

Giant cavernous malformations.

Stefan Linsler1.   

Abstract

Entities:  

Year:  2016        PMID: 27114646      PMCID: PMC4821923          DOI: 10.4103/0976-3147.178674

Source DB:  PubMed          Journal:  J Neurosci Rural Pract        ISSN: 0976-3155


× No keyword cloud information.
Cavernous malformations represent about 10% of all vascular lesions of the brain.[123] They occur equally among men and female and usually present between the ages of 20 and 40 years. Cavernous malformations are most commonly located in the cerebral hemispheres, especially in the parietal lobe and thalamus.[45] Intracranial extra-axial cavernomas are relatively rare.[6] They are congenital in origin and are differentiated clearly from vascular tumors. As these lesions are essentially nonspace occupying and angiographically occult, the detection rate and the clinical interest in this entity have increased in the era of computer tomography and magnetic resonance (MR) imaging. Cavernous hemangiomas are more often identified as small lesions, which show evidence of hemorrhage. Cavernous malformations can present with headaches, seizures, neurological deficits, or can be found incidentally. The natural history of cavernous malformations has been studied in detail and is still under debate.[78] When hemorrhages occur, cavernous malformations have a high risk of rebleeding, with rebleeding rates of, for example, brainstem cavernous malformations ranging from 5% to 35% per year. Although intracranial intra-axial and extra-axial cavernomas are reported, giant intracranial cavernomas are extremely rare. Giant cavernomas are usually found in the gastrointestinal tract, especially in the liver and spleen and also in the subcutaneous region. Giant intracranial extracerebral cavernomas are reported in the scalp, pericranium, pituitary gland, middle cranial fossa, and cavernous sinus.[9101112] Giant intracranial, intra-axial cerebral parenchymal cavernomas are reported in some case reports and reviews as presented in this case. The relationship between the size of cavernoma and probability of hemorrhage or long-term neurological morbidity is still under debate. However, the growth of intracerebral cavernomas is accentuated by repeated microhemorrhages into the cavernoma. The large size of giant cavernomas, reported in some cases, may be explained on this hypothesis. There might also be a possibility of accelerated growth due to hormonal changes during puberty. The growth of cavernoma over a time period and the correlative MR imaging changes are reported in 38% of patients.[13] They exhibit a range of dynamic behavior including increase or decrease in size, de novo formation as well as progression through a series of characteristic MR imaging appearances.[13] Surgical intervention is the treatment of choice for all cavernous malformations.[3] Thereby, the localization may be influence the indication und decision for surgery. It is also indicated in patients with hemorrhages which have a cavernoma that presents to the pial surface in eloquent areas or brainstem. Thereby, the surgical approach is dictated by the location of the cavernous malformation and using available microsurgical techniques is ideal since the cavernoma is well circumscribed to the surrounding brain tissue. The main goal of modern surgical treatment of cavernous malformations is minimizing the amount of healthy tissue that must be traversed to achieve a complete resection.[11415] The risks and benefits of surgical treatment must be weighed against possible morbidity resulting from surgery. Thus and in consequence of modern MR imaging, excellent neuronavigation systems, minimally invasive approaches and new surgical tools surgical resection can be also performed in cavernous malformations localized in eloquent areas[15] and should also be performed in the case of giant cavernous malformations. In modern neurosurgery, the surgical goal of total resection of giant cavernous malformations without any surgical morbidity should be possible in nearly all cases.
  14 in total

Review 1.  The natural history of cavernous malformations.

Authors:  J L Moriarity; R E Clatterbuck; D Rigamonti
Journal:  Neurosurg Clin N Am       Date:  1999-07       Impact factor: 2.509

2.  Giant interdural cavernous hemangioma at the convexity. Case illustration.

Authors:  A Hyodo; K Yanaka; O Higuchi; Y Tomono; T Nose
Journal:  J Neurosurg       Date:  2000-03       Impact factor: 5.115

Review 3.  Giant intracranial and extracranial cavernous malformation. Case report.

Authors:  J L Voelker; D H Stewart; S S Schochet
Journal:  J Neurosurg       Date:  1998-09       Impact factor: 5.115

4.  Intracranial cavernous angioma: presentation and management.

Authors:  P Tagle; I Huete; J Méndez; S del Villar
Journal:  J Neurosurg       Date:  1986-05       Impact factor: 5.115

5.  Giant pituitary cavernous hemangioma: case report.

Authors:  M E Sansone; B H Liwnicz; T I Mandybur
Journal:  J Neurosurg       Date:  1980-07       Impact factor: 5.115

6.  Giant cavernous hemangioma of the scalp.

Authors:  Y Tüzün; C R Kayaoğlu; E Takçi; H H Kadioğlu; S Suma; M Oztürk; I H Aydin
Journal:  Zentralbl Neurochir       Date:  1998

7.  Giant congenital capillary hemangioma of pericranium--case report.

Authors:  Y Tokuda; T Uozumi; K Sakoda; K Yamada; M Yamanaka; S Nomura; T Hamasaki
Journal:  Neurol Med Chir (Tokyo)       Date:  1990-12       Impact factor: 1.742

8.  Cavernous malformations of the basal ganglia and thalamus.

Authors:  Bradley A Gross; H Hunt Batjer; Issam A Awad; Bernard R Bendok
Journal:  Neurosurgery       Date:  2009-07       Impact factor: 4.654

9.  The natural history of familial cavernous malformations: results of an ongoing study.

Authors:  J M Zabramski; T M Wascher; R F Spetzler; B Johnson; J Golfinos; B P Drayer; B Brown; D Rigamonti; G Brown
Journal:  J Neurosurg       Date:  1994-03       Impact factor: 5.115

10.  Endoscopic Endonasal Transclival Resection of a Brainstem Cavernoma: A Detailed Account of Our Technique and Comparison with the Literature.

Authors:  Stefan Linsler; Joachim Oertel
Journal:  World Neurosurg       Date:  2015-09-02       Impact factor: 2.104

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.